Inclusion of Strep-tag II in design of antigen receptors for T-cell immunotherapy

Nat Biotechnol. 2016 Apr;34(4):430-4. doi: 10.1038/nbt.3461. Epub 2016 Feb 22.


Adoptive immunotherapy with genetically engineered T cells has the potential to treat cancer and other diseases. The introduction of Strep-tag II sequences into specific sites in synthetic chimeric antigen receptors or natural T-cell receptors of diverse specificities provides engineered T cells with a marker for identification and rapid purification, a method for tailoring spacer length of chimeric receptors for optimal function, and a functional element for selective antibody-coated, microbead-driven, large-scale expansion. These receptor designs facilitate cGMP manufacturing of pure populations of engineered T cells for adoptive T-cell therapies and enable in vivo tracking and retrieval of transferred cells for downstream research applications.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Tracking
  • Female
  • Genetic Engineering / methods*
  • Humans
  • Immunotherapy, Adoptive / methods*
  • Mice
  • Mice, Transgenic
  • Oligopeptides / chemistry
  • Oligopeptides / genetics*
  • Oligopeptides / metabolism
  • Receptors, Antigen, T-Cell* / chemistry
  • Receptors, Antigen, T-Cell* / genetics
  • Receptors, Antigen, T-Cell* / metabolism
  • T-Lymphocytes / chemistry*
  • T-Lymphocytes / cytology*


  • Oligopeptides
  • Receptors, Antigen, T-Cell
  • Trp-Ser- His-Pro-Gln-Phe-Glu-Lys